durvalumab,paclitaxel,carboplatin,cisplatin,gemcitabine,pemetrexed
astrazeneca
['nsclc', 'aegean', 'sclc', '$azn']
and now we have numerical data for $azn aegean study in neoadjuvant nsclc. hr for efs is 0.68 (p=0.004) #aacr23 
Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.